Brian Bell

CEO and Director

Brian Bell began his career as a technology and health care analyst for several mutual fund companies, including PIMCO Advisors ($180 billion in assets under management) and most recently with Seed Capital Partners, LLC, an early stage venture fund with backing from Softbank Corporation and JP Morgan Partners.

At Seed Capital, his responsibilities ranged from due diligence, development of an executive network of industry experts, and investment recommendation, to hands on business development, strategic planning, and merger and acquisition activity on behalf of specific portfolio companies.

He is a director of the WNY Venture Association, and a founder of Buffalo Angel Network, a network of currently 40 accredited investors focused on early stage investments in the region. Brian has provided executive management support for Medical Conservation Devices and First Wave Products Group, where he is also co-inventor on three patents.

Brian Bell

CEO and Director

Brian Bell began his career as a technology and health care analyst for several mutual fund companies, including PIMCO Advisors ($180 billion in assets under management) and most recently with Seed Capital Partners, LLC, an early stage venture fund with backing from Softbank Corporation and JP Morgan Partners.

At Seed Capital, his responsibilities ranged from due diligence, development of an executive network of industry experts, and investment recommendation, to hands on business development, strategic planning, and merger and acquisition activity on behalf of specific portfolio companies.

He is a director of the WNY Venture Association, and a founder of Buffalo Angel Network, a network of currently 40 accredited investors focused on early stage investments in the region. Brian has provided executive management support for Medical Conservation Devices and First Wave Products Group, where he is also co-inventor on three patents.

Bradley Fuhrman, MD

Founder & Chief Medical Officer

Dr. Fuhrman trained in Pediatrics, Neonatology and Pediatric Cardiology at the University of Minnesota, and went on to be Board Certified in those specialties and in Pediatric Critical Care Medicine. He developed the first Pediatric ICU at U of MN in 1979 and then practiced that subspecialty for over 3 decades at the U of MN, Children’s Hospital of Pittsburgh, Children’s Hospital of Buffalo and El Paso Children’s. He served on and chaired the ABP Sub-Board of Pediatric Critical Care. He chaired the Pediatric Section and was later elected Council Member of the Society of Critical Care Medicine. Dr. Fuhrman served on numerous editorial boards, including those of the Journal of Pediatrics, Critical Care Medicine and Pediatric Critical Care Medicine. Together with Jerry Zimmerman, he edited all 5 editions of Fuhrman and Zimmerman’s Pediatric Critical Care. Dr. Fuhrman received the Distinguished Career Award of the Critical Care Section of the American Academy of Pediatrics in 2004 and was named a Master of Critical Care by the Society of Critical Care Medicine in 2016. Over the course of his career, Dr. Fuhrman has developed numerous inventions. He has been awarded a dozen US and numerous foreign patents, many of which deal with rebreathing technology. He is a founder of Medical Conservation Devices, LLC and continues to serve on their Board of Directors. In March 2018, after almost 7 years as Chair of the Department of Pediatrics at Texas Tech University Health Sciences Center in El Paso and Physician-in-Chief of El Paso Children’s Hospital, Dr. Fuhrman stepped down to devote more of his time to academic pursuits and to Medical Conservation Devices.

Bradley Fuhrman, MD

Founder & Chief Medical Officer

Dr. Fuhrman trained in Pediatrics, Neonatology and Pediatric Cardiology at the University of Minnesota, and went on to be Board Certified in those specialties and in Pediatric Critical Care Medicine. He developed the first Pediatric ICU at U of MN in 1979 and then practiced that subspecialty for over 3 decades at the U of MN, Children’s Hospital of Pittsburgh, Children’s Hospital of Buffalo and El Paso Children’s. He served on and chaired the ABP Sub-Board of Pediatric Critical Care. He chaired the Pediatric Section and was later elected Council Member of the Society of Critical Care Medicine. Dr. Fuhrman served on numerous editorial boards, including those of the Journal of Pediatrics, Critical Care Medicine and Pediatric Critical Care Medicine. Together with Jerry Zimmerman, he edited all 5 editions of Fuhrman and Zimmerman’s Pediatric Critical Care. Dr. Fuhrman received the Distinguished Career Award of the Critical Care Section of the American Academy of Pediatrics in 2004 and was named a Master of Critical Care by the Society of Critical Care Medicine in 2016. Over the course of his career, Dr. Fuhrman has developed numerous inventions. He has been awarded a dozen US and numerous foreign patents, many of which deal with rebreathing technology. He is a founder of Medical Conservation Devices, LLC and continues to serve on their Board of Directors. In March 2018, after almost 7 years as Chair of the Department of Pediatrics at Texas Tech University Health Sciences Center in El Paso and Physician-in-Chief of El Paso Children’s Hospital, Dr. Fuhrman stepped down to devote more of his time to academic pursuits and to Medical Conservation Devices.

Doug DuFaux

Technical Director

Mr. DuFaux combines over 20 years of experience in product and process development with extensive experience in manufacturing development, engineering, customer relationships, and intellectual property. His unique combination of industry experience, including medical devices, electronics & controls, advanced materials, consumer products, and chemicals, provides Mr. DuFaux with an effective development perspective. Formerly a Director for Product Commercialization at NanoDynamics and VP of Operations at AP Materials, Mr. DuFaux is a Licensed Professional Engineer and has earned a Bachelors and Masters Degree in Mechanical Engineering.

• Developed proprietary systems and packaging for medical products company entering pharmaceutical accessories market

• Principal Investigator for a Dept. of Defense program aimed at developing an FDA approved semi-automated re-breathing ventilation technology for delivery of volatile agents for field-deployable analgesia and anesthesia
Supporting development and quality process efforts with the near-term goal of 510(k) submission

Modification of designs include single-point, mobile, ICU capabilities

• Directed development of tri-band optical sensors for two-year National Institutes of Health program
Sensors were coupled with an enzyme-based instrument for detection of hazardous chemicals for DHS applications;

• Led product development and manufacturing of a hollow-core golf ball:
Led the development and implementation of a multi-stage manufacturing process for high-rate production of metal golf ball cores; Worked with quality team to ensure targets met;
Achieved USGA certification after 18-month negotiation with USGA;
Received national press coverage from sources including The Wall Street Journal, CBS Evening News, USA Today, The Buffalo News, Design News, among others.

Doug DuFaux

Technical Director

Mr. DuFaux combines over 20 years of experience in product and process development with extensive experience in manufacturing development, engineering, customer relationships, and intellectual property. His unique combination of industry experience, including medical devices, electronics & controls, advanced materials, consumer products, and chemicals, provides Mr. DuFaux with an effective development perspective. Formerly a Director for Product Commercialization at NanoDynamics and VP of Operations at AP Materials, Mr. DuFaux is a Licensed Professional Engineer and has earned a Bachelors and Masters Degree in Mechanical Engineering.

• Developed proprietary systems and packaging for medical products company entering pharmaceutical accessories market

• Principal Investigator for a Dept. of Defense program aimed at developing an FDA approved semi-automated re-breathing ventilation technology for delivery of volatile agents for field-deployable analgesia and anesthesia
Supporting development and quality process efforts with the near-term goal of 510(k) submission

Modification of designs include single-point, mobile, ICU capabilities

• Directed development of tri-band optical sensors for two-year National Institutes of Health program
Sensors were coupled with an enzyme-based instrument for detection of hazardous chemicals for DHS applications;

• Led product development and manufacturing of a hollow-core golf ball:
Led the development and implementation of a multi-stage manufacturing process for high-rate production of metal golf ball cores; Worked with quality team to ensure targets met;
Achieved USGA certification after 18-month negotiation with USGA;
Received national press coverage from sources including The Wall Street Journal, CBS Evening News, USA Today, The Buffalo News, Design News, among others.

Joel Kanter

Chairman

Mr. Joel Kanter has served as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999, Mr. Kanter also served as the Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq: WNUT). Walnut Financial’s primary business focus was the provision of different forms of financing to small business, by providing equity financing to start-up and early-stage development companies, providing bridge financing to small and medium-sized companies, and providing later-stage institutional financing to more mature enterprises. The Company was sold to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million. Walnut was an early-stage investor in a diverse array of health care companies that have included BioHorizons, which has grown to be one of the largest dental implant companies in the world; Clarisonic, which was sold to L’Oreal for $525 million; Encore Medical, an orthopedic implant company that is now owned by Blackstone; GranCare, which grew to be the third largest long-term care company in the country; HealthCare COMPARE, the first utilization review company in the country and first nationwide PPO; I-Flow, a catheter and pain pump developer that was sold to Kimberly Clark for over $400 million; Prolor, a life sciences company that lengthened the life of protiens and was sold for $350 million; Sonicare Toothbrushes, which was sold to Phillips for $375 million, and some 300+ other companies. Mr. Kanter is a graduate of Tulane University.

Mr. Kanter is also a Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University, the Country’s first Online University. He is also the current Board Chair of the Black Student Fund, the Education Committee Chair of the Kennedy Center’s National Committee on the Performing Arts, and serves as an appointee of the State Legislature to the Gubernatorial Virginia Israel Advisory Board.

Joel Kanter

Chairman

Mr. Joel Kanter has served as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999, Mr. Kanter also served as the Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company (Nasdaq: WNUT). Walnut Financial’s primary business focus was the provision of different forms of financing to small business, by providing equity financing to start-up and early-stage development companies, providing bridge financing to small and medium-sized companies, and providing later-stage institutional financing to more mature enterprises. The Company was sold to Tower Hill Capital Group in 1999 in a transaction valued at approximately $400 million. Walnut was an early-stage investor in a diverse array of health care companies that have included BioHorizons, which has grown to be one of the largest dental implant companies in the world; Clarisonic, which was sold to L’Oreal for $525 million; Encore Medical, an orthopedic implant company that is now owned by Blackstone; GranCare, which grew to be the third largest long-term care company in the country; HealthCare COMPARE, the first utilization review company in the country and first nationwide PPO; I-Flow, a catheter and pain pump developer that was sold to Kimberly Clark for over $400 million; Prolor, a life sciences company that lengthened the life of protiens and was sold for $350 million; Sonicare Toothbrushes, which was sold to Phillips for $375 million, and some 300+ other companies. Mr. Kanter is a graduate of Tulane University.

Mr. Kanter is also a Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University, the Country’s first Online University. He is also the current Board Chair of the Black Student Fund, the Education Committee Chair of the Kennedy Center’s National Committee on the Performing Arts, and serves as an appointee of the State Legislature to the Gubernatorial Virginia Israel Advisory Board.

Gene Burleson

Director

Gene has been a First Wave Tech Director since January 2011. He served as Chairman (1989-1997) and CEO and President (1990-1997) of GranCare, Inc., which, under his management, grew from under $10 million in revenue to become one of the nation’s largest publicly traded long-term healthcare providers with revenues in excess of $1 billion.

Following the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services, he served as CEO and a Director of Vitalink a provider of pharmacy services to skilled nursing facilities. Both GranCare and Vitalink were NYSE-listed companies. In addition, Mr. Burleson is involved with several private companies including; DTS America, Inc. a provider of integrated documentation services to surgeons and hospitals through multimedia technology; Marina Medical, Inc. a provider of medical billing and accounts receivable management services to hospital based physicians; `He has an extensive and successful track record of consolidation within the healthcare industry.

In 2006, along with other established life science executives, Mr. Burleson joined MediSync, a consolidator of complementary, high-value, niche contract research organizations, site management organizations and related businesses. Mr. Burleson currently serves on the Board of Directors of SunLink Health Systems (AMEX:SSY), a provider of acute healthcare services and Vyteris, Inc. a company engaged in the development of electronically controlled transdermal drug delivery systems.

Previously he served as Chairman and CEO of Pet DRx Corporation a provider of primary and specialty healthcare for companion animals, as Chairman of Mariner Post-Acute Network, Alterra Healthcare Corporation, and as a Director of Deckers Outdoor Corporation and Prospect Medical Holdings (AMEX:PZZ), among others.

Gene Burleson

Director

Gene has been a First Wave Tech Director since January 2011. He served as Chairman (1989-1997) and CEO and President (1990-1997) of GranCare, Inc., which, under his management, grew from under $10 million in revenue to become one of the nation’s largest publicly traded long-term healthcare providers with revenues in excess of $1 billion.

Following the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services, he served as CEO and a Director of Vitalink a provider of pharmacy services to skilled nursing facilities. Both GranCare and Vitalink were NYSE-listed companies. In addition, Mr. Burleson is involved with several private companies including; DTS America, Inc. a provider of integrated documentation services to surgeons and hospitals through multimedia technology; Marina Medical, Inc. a provider of medical billing and accounts receivable management services to hospital based physicians; `He has an extensive and successful track record of consolidation within the healthcare industry.

In 2006, along with other established life science executives, Mr. Burleson joined MediSync, a consolidator of complementary, high-value, niche contract research organizations, site management organizations and related businesses. Mr. Burleson currently serves on the Board of Directors of SunLink Health Systems (AMEX:SSY), a provider of acute healthcare services and Vyteris, Inc. a company engaged in the development of electronically controlled transdermal drug delivery systems.

Previously he served as Chairman and CEO of Pet DRx Corporation a provider of primary and specialty healthcare for companion animals, as Chairman of Mariner Post-Acute Network, Alterra Healthcare Corporation, and as a Director of Deckers Outdoor Corporation and Prospect Medical Holdings (AMEX:PZZ), among others.

Alastair Clemow, PhD

Director

Dr. Clemow serves as Chairman of Ensemble Orthopedics, an upper extremity implant company. Prior to this, he managed a number of early stage technologies including Regentis Biomaterials, Nexgen Spine and Minimally Invasive Surgical Technologies. Previously, Dr. Clemow spent 20 years at Johnson & Johnson in senior executive positions including Worldwide Vice President for Business Development. Dr. Clemow graduated from the University of Surrey (UK) with a BSc and PhD in metallurgy and from Columbia University with an MBA. He is a Past President of the Society for Biomaterials.

Alastair Clemow, PhD

Director

Dr. Clemow serves as Chairman of Ensemble Orthopedics, an upper extremity implant company. Prior to this, he managed a number of early stage technologies including Regentis Biomaterials, Nexgen Spine and Minimally Invasive Surgical Technologies. Previously, Dr. Clemow spent 20 years at Johnson & Johnson in senior executive positions including Worldwide Vice President for Business Development. Dr. Clemow graduated from the University of Surrey (UK) with a BSc and PhD in metallurgy and from Columbia University with an MBA. He is a Past President of the Society for Biomaterials.

Raymond Dean Hautamaki MD FCCP FACP

Director

Raymond Dean Hautamaki, MD is board certified internal medicine-pulmonary/ critical care physician practicing in Sarasota, Florida. He attended the University of Florida in Gainesville , Florida for undergraduate studies and medical school. He was inducted into AOA his junior year of medical school and graduated from the University of Florida College of Medicine with honors along with honors in research. Dr. Hautamaki was a general surgical resident at the University of Florida at Shands Hospital in Gainesville Florida and then completed his Internal Medicine residency and pulmonary/critical care fellowship at Washington University School of Medicine-Barnes/Jewish Hospital system.

Since 1997 Dr. Hautamaki has been a practicing physician in Sarasota Florida. In 2008 he was the founding partner of Hautamaki & Horiuchi Personal Physicians of Sarasota providing internal medicine/pulmonary and critical care medical services. Dr. Hautamaki has worked in multiple roles at Sarasota Memorial Hospital (SMH), an 829-bed regional teaching medical center with an active Level II Trauma center. Over the last two decades Dr. Hautamaki has held multiple leadership positions within the SMH system including: Chairman of the Department of Medicine, Chief of Internal Medicine, Co-Medical Director of the Critical Care Division, and past member of the hospital’s medical executive committee. Dr. Hautamaki remains active teaching as an assistant clinical professor with Florida State College of Medicine. Dr. Hautamaki is also a Co-Trustee for the Louis and Gloria Flanzer Philanthropic Trust, an organization dedicated to the health care and community-based social needs in Florida’s Suncoast. Dr. Hautamaki also serves as Chairman of the University of Florida College of Medicine’s Dean’s Leadership Council.

Dr. Hautamaki serves as director for several private and public biotechnology companies which have included: Wafergen Biosystems, Fibralign Corporation, and 20/20 Genesystems.

Raymond Dean Hautamaki MD FCCP FACP

Director

Raymond Dean Hautamaki, MD is board certified internal medicine-pulmonary/ critical care physician practicing in Sarasota, Florida. He attended the University of Florida in Gainesville , Florida for undergraduate studies and medical school. He was inducted into AOA his junior year of medical school and graduated from the University of Florida College of Medicine with honors along with honors in research. Dr. Hautamaki was a general surgical resident at the University of Florida at Shands Hospital in Gainesville Florida and then completed his Internal Medicine residency and pulmonary/critical care fellowship at Washington University School of Medicine-Barnes/Jewish Hospital system.

Since 1997 Dr. Hautamaki has been a practicing physician in Sarasota Florida. In 2008 he was the founding partner of Hautamaki & Horiuchi Personal Physicians of Sarasota providing internal medicine/pulmonary and critical care medical services. Dr. Hautamaki has worked in multiple roles at Sarasota Memorial Hospital (SMH), an 829-bed regional teaching medical center with an active Level II Trauma center. Over the last two decades Dr. Hautamaki has held multiple leadership positions within the SMH system including: Chairman of the Department of Medicine, Chief of Internal Medicine, Co-Medical Director of the Critical Care Division, and past member of the hospital’s medical executive committee. Dr. Hautamaki remains active teaching as an assistant clinical professor with Florida State College of Medicine. Dr. Hautamaki is also a Co-Trustee for the Louis and Gloria Flanzer Philanthropic Trust, an organization dedicated to the health care and community-based social needs in Florida’s Suncoast. Dr. Hautamaki also serves as Chairman of the University of Florida College of Medicine’s Dean’s Leadership Council.

Dr. Hautamaki serves as director for several private and public biotechnology companies which have included: Wafergen Biosystems, Fibralign Corporation, and 20/20 Genesystems.

Wayne Hellman, MD

Director

Wayne Hellman is founder of Advanced Lighting Technologies (ADLT) and served as its CEO since the company’s inception in 1983 to 2014. Prior to this, he worked at General Electric for 16 years. Mr. Hellman grew ADLT from $900,000 in first year revenues to over $250 million. ADLT has significant manufacturing operations in Germany with its thin film coating and optics facility, a specialty chemical operation in the US, and three large factories in India where it’s lighting products are manufactured. Mr. Hellman’s expertise is in product development with the focus on leadership products that set the standards for new applications. High market share is the goal for most of the product strategies. To pursue these many product innovations and to fund the growth, Mr. Hellman has raised over $500 million during ADLT ‘s 30-year growth history. After his retirement in 2014, he is now Managing Partner of Hellman New Ventures LLC. Mr Hellman graduated from Ohio University with a degree in Physics.

Wayne Hellman, MD

Director

Wayne Hellman is founder of Advanced Lighting Technologies (ADLT) and served as its CEO since the company’s inception in 1983 to 2014. Prior to this, he worked at General Electric for 16 years. Mr. Hellman grew ADLT from $900,000 in first year revenues to over $250 million. ADLT has significant manufacturing operations in Germany with its thin film coating and optics facility, a specialty chemical operation in the US, and three large factories in India where it’s lighting products are manufactured. Mr. Hellman’s expertise is in product development with the focus on leadership products that set the standards for new applications. High market share is the goal for most of the product strategies. To pursue these many product innovations and to fund the growth, Mr. Hellman has raised over $500 million during ADLT ‘s 30-year growth history. After his retirement in 2014, he is now Managing Partner of Hellman New Ventures LLC. Mr Hellman graduated from Ohio University with a degree in Physics.

Cary W. Sucoff

Director

Cary Sucoff has over 30 years of securities industry experience. Mr. Sucoff currently owns and operates Equity Source Partners, LLC an advisory and consulting firm. He has participated in the financing of hundreds of public and private companies.

Mr. Sucoff currently serves on the following Boards of Directors:

Contrafect Corp., (CFRX), engaged in the development of new treatments for infectious diseases utilizing proprietary antibody and lysin technology;

Legacy Education Alliance, Inc. (LEAI), provides educational training seminars, conferences, and services in the United States, Canada, the United Kingdom, and internationally;

First Wave Technologies, Inc.; brings to the commercial market new and innovative medical device technologies;

Galimedix Therapeutics, Inc. – pursuing small molecule breakthrough licensed from Tel Aviv University working on potentially revolutionary treatments for Glaucoma and Dry Age-related Macular Degeneration.
In addition, Mr. Sucoff currently serves as a consultant to Sapience Therapeutics, Inc., an early stage Biotech company focusing on Glioblastoma.

Mr. Sucoff, a former New York City prosecutor is the Past President of New England Law/Boston and has been a member of its Board of Trustees for over 25 years. He is Chairman of the Endowment Committee.

Mr. Sucoff received a B.A. from SUNY Binghamton (1974) and a J.D. from New England School of Law (1977) where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.

Cary W. Sucoff

Director

Cary Sucoff has over 30 years of securities industry experience. Mr. Sucoff currently owns and operates Equity Source Partners, LLC an advisory and consulting firm. He has participated in the financing of hundreds of public and private companies.

Mr. Sucoff currently serves on the following Boards of Directors:

Contrafect Corp., (CFRX), engaged in the development of new treatments for infectious diseases utilizing proprietary antibody and lysin technology;

Legacy Education Alliance, Inc. (LEAI), provides educational training seminars, conferences, and services in the United States, Canada, the United Kingdom, and internationally;

First Wave Technologies, Inc.; brings to the commercial market new and innovative medical device technologies;

Galimedix Therapeutics, Inc. – pursuing small molecule breakthrough licensed from Tel Aviv University working on potentially revolutionary treatments for Glaucoma and Dry Age-related Macular Degeneration.
In addition, Mr. Sucoff currently serves as a consultant to Sapience Therapeutics, Inc., an early stage Biotech company focusing on Glioblastoma.

Mr. Sucoff, a former New York City prosecutor is the Past President of New England Law/Boston and has been a member of its Board of Trustees for over 25 years. He is Chairman of the Endowment Committee.

Mr. Sucoff received a B.A. from SUNY Binghamton (1974) and a J.D. from New England School of Law (1977) where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.

Gene Bauer, MD

Director

Eugene Bauer is immediate past co-founder, Chief Medical Officer and member of the board of directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company. Prior to founding Dermira, he served as a member of the board of directors of Peplin, Inc., where he also was its President and Chief Medical Officer, until Peplin’s acquisition by LEO Pharma in 2009. During 2004-2008, Dr. Bauer was Chief Executive Officer of Neosil, Inc., a clinical stage dermatology company, acquired by Peplin, Inc., in 2008. Prior to that he was co-founder and member of the board of directors at Connetics, a commercial dermatology company acquired by Stiefel Laboratories in 2009. Before initiating a career in industry, Dr. Bauer served as Chairman of the Department of Dermatology (1988-1995) and as the Dean of the School of Medicine (1995-2001) of Stanford University. He is currently Lucy Becker Professor, Emeritus, in Stanford University School of Medicine, a position he has held since 2002.

Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc.

Dr. Bauer was a National Institutes of Health (NIH)-funded investigator for 25 years and has served on numerous advisory groups for the NIH. He has been elected to several honorific societies, including the National Academy of Medicine of the United States.

Dr. Bauer received a B.S. in medicine and an M.D. from Northwestern University.

Gene Bauer, MD

Director

Eugene Bauer is immediate past co-founder, Chief Medical Officer and member of the board of directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company. Prior to founding Dermira, he served as a member of the board of directors of Peplin, Inc., where he also was its President and Chief Medical Officer, until Peplin’s acquisition by LEO Pharma in 2009. During 2004-2008, Dr. Bauer was Chief Executive Officer of Neosil, Inc., a clinical stage dermatology company, acquired by Peplin, Inc., in 2008. Prior to that he was co-founder and member of the board of directors at Connetics, a commercial dermatology company acquired by Stiefel Laboratories in 2009. Before initiating a career in industry, Dr. Bauer served as Chairman of the Department of Dermatology (1988-1995) and as the Dean of the School of Medicine (1995-2001) of Stanford University. He is currently Lucy Becker Professor, Emeritus, in Stanford University School of Medicine, a position he has held since 2002.

Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc.

Dr. Bauer was a National Institutes of Health (NIH)-funded investigator for 25 years and has served on numerous advisory groups for the NIH. He has been elected to several honorific societies, including the National Academy of Medicine of the United States.

Dr. Bauer received a B.S. in medicine and an M.D. from Northwestern University.

Adi Raviv

Chief Financial Officer

Mr. Raviv sits on the board of directors of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) where he chairs the audit and finance committees and is a member of the compensation and strategy committees. He founded HTI Associates LLC in 1996 and since then has served as the managing member of this management consultancy firm that also provides outsourced C-level functions. From 2021 to 2022 Mr. Raviv was the interim CEO of Mirror Biologics, Inc., a clinical stage biopharmaceutical company.

From April 2016 he has also been a Principal at Capacity Funding LLC, a company providing working capital solutions to small businesses. Prior to that, Mr. Raviv served in a chief financial officer position in several other private and public companies. Mr. Raviv has extensive capital markets, cash management, corporate finance, investment banking, investor relations, restructuring, tax and treasury, and transactional experience. He co-founded THCG, Inc. (Nasdaq: THCG), a publicly traded technology merchant banking and consulting company (where he was also CFO), and has been involved with companies in challenging startup, growth, and turnaround environments.

Mr. Raviv has served on the boards of directors of many private and several public companies, as well as various non-profit entities. He received a bachelor’s degree in International Relations with honors from the Hebrew University of Jerusalem and an MBA, with honors, from Columbia University in New York City.

Adi Raviv

Chief Financial Officer

Mr. Raviv sits on the board of directors of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) where he chairs the audit and finance committees and is a member of the compensation and strategy committees. He founded HTI Associates LLC in 1996 and since then has served as the managing member of this management consultancy firm that also provides outsourced C-level functions. From 2021 to 2022 Mr. Raviv was the interim CEO of Mirror Biologics, Inc., a clinical stage biopharmaceutical company.

From April 2016 he has also been a Principal at Capacity Funding LLC, a company providing working capital solutions to small businesses. Prior to that, Mr. Raviv served in a chief financial officer position in several other private and public companies. Mr. Raviv has extensive capital markets, cash management, corporate finance, investment banking, investor relations, restructuring, tax and treasury, and transactional experience. He co-founded THCG, Inc. (Nasdaq: THCG), a publicly traded technology merchant banking and consulting company (where he was also CFO), and has been involved with companies in challenging startup, growth, and turnaround environments.

Mr. Raviv has served on the boards of directors of many private and several public companies, as well as various non-profit entities. He received a bachelor’s degree in International Relations with honors from the Hebrew University of Jerusalem and an MBA, with honors, from Columbia University in New York City.